SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934 (Amendment No. 3)*

Inozyme Pharma, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 (Title of Class of Securities)

45790W108 (CUSIP Number)

Robert Hopfner
Pivotal bioVenture Partners Fund I U.G.P. Ltd
501 2nd Street, Suite 200
San Francisco, CA 94107
(415) 697-1002
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 $\begin{array}{c} August\ 1,\ 2023 \\ \text{(Date of Event Which Requires Filing of this Statement)} \end{array}$

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. \Box

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	Names	of Re	eporting Persons.		
	Trained of Treporting Teleports				
	Pivotal bioVenture Partners Fund I, L.P.				
2.			ppropriate Box if a Member of a Group (See Instructions)		
	(a) □	(I	o) ⊠		
3.	SEC U	Ise On	lv		
3.	DEG C	, sc O11	-y		
4.	Source	of Fu	ands (See Instructions)		
	WC				
5.		if Dic	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
٥.	Circek	11 1513	closure of Legal 110ccculligs is required 1 distant to fichis 2(d) of 2(e)		
6.	Citizeı	nship o	or Place of Organization		
		- 1			
	Cayma				
		7.	Sole Voting Power		
Nu	mber of		0		
	hares	8.	Shared Voting Power		
	eficially ned by				
	Each		2,923,110		
	porting	9.	Sole Dispositive Power		
	erson		0		
	With	10.	Shared Dispositive Power		
			·		
			2,923,110		
11.	Aggre	gate A	mount Beneficially Owned by Each Reporting Person		
	2,923,	110			
12.			Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)		
1	Gileen	11 1110	2-286-Sate 1 mount in 110 ii (12) 2.iciaaco Geram onaco (Gee moraciono)		
13.	Percen	t of C	lass Represented by Amount in Row (11)		
	6.2%				
14.		f Ren	orting Person (See Instructions)		
14.	4. Type of Reporting Person (See Instructions)				
	PN				

1.	Names of Reporting Persons.				
	Pivotal bioVenture Partners Fund II, L.P.				
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) □ (b) ⊠				
3.	SEC U	Jse On	ly		
4.	Source	of Fu	ands (See Instructions)		
	WC				
5.		if Dis	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citizeı	nship (or Place of Organization		
	Cayma	an Isla	nds		
		7.	Sole Voting Power		
Nu	mber of		0		
	hares eficially	8.	Shared Voting Power		
Ow	ned by		1,571,741		
	Each porting	9.	Sole Dispositive Power		
	erson With		0		
	***************************************	10.	Shared Dispositive Power		
			1,571,741		
11.	Aggre	gate A	mount Beneficially Owned by Each Reporting Person		
	1,571,	741			
12.	Check	if the	Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)		
13.	Percen	t of C	lass Represented by Amount in Row (11)		
	3.3%				
14.	Type o	f Rep	orting Person (See Instructions)		
	PN				

1.	Names of Reporting Persons.				
	Pivotal bioVenture Partners Fund II G.P. Ltd				
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) □ (b) ⊠				
3.	SEC U	Jse On	ly		
4.	Source	of Fu	ands (See Instructions)		
	AF				
5.	Check	if Dis	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citizeı	nship (or Place of Organization		
	Cayma	an Isla	nds		
		7.	Sole Voting Power		
Nu	mber of		0		
	hares eficially	8.	Shared Voting Power		
Ow	ned by		1,571,741		
Re	Each porting	9.	Sole Dispositive Power		
	erson With		0		
		10.	Shared Dispositive Power		
			1,571,741		
11.	Aggre	gate A	mount Beneficially Owned by Each Reporting Person		
	1,571,				
12.	. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)				
13.	Percen	of C	lass Represented by Amount in Row (11)		
	3.3%				
14.	Type o	f Repo	orting Person (See Instructions)		
	PN				

1.	Names	s of Re	eporting Persons.		
1.	runies of reporting 1 crooks.				
	Pivotal bioVenture Partners Fund I G.P., L.P.				
2.	Check the Appropriate Box if a Member of a Group (See Instructions)				
	(a) □	(l	o) ⊠		
3.	SEC U	Ico On	lu.		
3.	SEC C	ise On	ny .		
4.	Source	of Fu	ands (See Instructions)		
_	AF Charle	:f D:-	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
5.	Спеск	II DIS	closure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)		
6.	Citizeı	nship o	or Place of Organization		
	Cayma				
		7.	Sole Voting Power		
Nu	mber of		0		
	hares	8.	Shared Voting Power		
	eficially ned by				
	Each		2,923,110		
Re	porting	9.	Sole Dispositive Power		
	erson With		0		
	vviui	10.	Shared Dispositive Power		
			2,923,110		
11.	Aggre	gate A	mount Beneficially Owned by Each Reporting Person		
	2,923,	110			
12.			Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)		
13.	Percen	t of C	lass Represented by Amount in Row (11)		
	6.2%				
14.		of Ren	orting Person (See Instructions)		
,	Type of Reporting Letson (occ instructions)				
	PN				
	-				

1.	Names of Reporting Persons.				
			enture Partners Fund I U.G.P. Ltd		
2.	Check (a) □		ppropriate Box if a Member of a Group (See Instructions)) 区		
3.	SEC U	Jse Or	ly		
4.	Source	of Fu	ands (See Instructions)		
	WC				
5.	Check	if Dis	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citizei	nship (or Place of Organization		
		•			
	Cayma	an Isla			
		7.	Sole Voting Power		
Nui	mber of		0		
	hares	8.	Shared Voting Power		
	eficially				
	ned by Each		2,923,110		
Re	porting	9.	Sole Dispositive Power		
	erson		0		
,	With	10.	Shared Dispositive Power		
			Samuel — appearance — and		
			2,923,110		
11.	Aggre	gate A	mount Beneficially Owned by Each Reporting Person		
	2,923,	110			
12.			Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)		
12.	Circek	II tiic	riggregate filliount in Now (11) Excludes Certain Shares (See Instructions)		
13.	Percen	t of C	lass Represented by Amount in Row (11)		
	6.2%				
14.		of Rep	orting Person (See Instructions)		
	J.1	1			
	CO				

1.	Names of Reporting Persons.				
	Pivotal Partners Ltd				
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) □ (b) ⊠				
3.	SEC U	Jse On	ly		
4.	Source	e of Fu	unds (See Instructions)		
5.		if Dis	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citize	nship (or Place of Organization		
	Caym	an Isla	nds		
		7.	Sole Voting Power		
	mber of		0		
	hares eficially	8.	Shared Voting Power		
Ow	ned by Each		4,494,851		
Re	porting erson	9.	Sole Dispositive Power		
	With		0		
		10.	Shared Dispositive Power		
			4,494,851		
11.	Aggre	gate A	mount Beneficially Owned by Each Reporting Person		
	4,494,851				
12.	Check	if the	Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)		
13.	Percer	t of C	lass Represented by Amount in Row (11)		
	9.5%				
14.	Type o	of Rep	orting Person (See Instructions)		
	CO				

1.	Names of Reporting Persons.				
	Pivotal Life Sciences Holdings Limited				
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) □ (b) ⊠				
3.	SEC U	Jse Or	ly		
4.	Source	of Fu	ands (See Instructions)		
	AF				
5.	Check	if Dis	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citize	nship (or Place of Organization		
	Cayma	an Isla	nds		
	J	7.	Sole Voting Power		
	mber of		0		
	hares	8.	Shared Voting Power		
Ow	eficially ned by		4,494,851		
Re	Each porting	9.	Sole Dispositive Power		
	erson With		0		
	**1(11	10.	Shared Dispositive Power		
			4,494,851		
11.	Aggre	gate A	mount Beneficially Owned by Each Reporting Person		
11.	00-0	Bare 11	anount Denoticianly 6 wheat by Duch Reporting 2 closes		
	4,494,				
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)				
13.	Percen	t of C	lass Represented by Amount in Row (11)		
	9.5%				
14.	Type o	f Rep	orting Person (See Instructions)		
	CO				

1.	Names of Reporting Persons.				
	Nan Fung Life Sciences Holdings Limited				
2.	. Check the Appropriate Box if a Member of a Group (See Instructions) (a) □ (b) ⊠				
	. ,	Ì			
3.	SEC U	Jse Or	nly		
4.	Sourc	e of Fu	ands (See Instructions)		
	AF				
5.	Check	if Dis	sclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citize	nship (or Place of Organization		
	Britisl	n Virgi	n Islands		
		7.	Sole Voting Power		
	mber of		0		
Ben	hares eficially	8.	Shared Voting Power		
	ned by Each		4,494,851		
Re	porting	9.	Sole Dispositive Power		
	erson With		0		
		10.	Shared Dispositive Power		
			4,494,851		
11.	Aggre	gate A	mount Beneficially Owned by Each Reporting Person		
	4,494,851				
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)				
13.	Percent of Class Represented by Amount in Row (11)				
	9.5%				
14.	Type o	of Rep	orting Person (See Instructions)		
	СО				

1.	Names of Reporting Persons.				
	NF Investment Holdings Limited				
2.					
	(a) □	(I			
3.	SEC U	Ise On	ılv		
5.					
4.	Source	e of Fu	ands (See Instructions)		
	AF				
5.		if Dis	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	C:+:		or Place of Organization		
0.	Citize	изир (of Place of Organization		
	British	ı Virgi	n Islands		
		7.	Sole Voting Power		
Nu	mber of		0		
	hares	8.	Shared Voting Power		
	eficially ned by				
]	Each	0	4,494,851 Sole Dispositive Power		
	porting erson	9.	Sole Dispositive Power		
	With		0		
		10.	Shared Dispositive Power		
			4,494,851		
11.	Aggre	gate A	mount Beneficially Owned by Each Reporting Person		
10	4,494,		Aggregate Amount in Dec. (11) Findules Contrin Change (Con Instructions)		
12.	Cneck	11 the	Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)		
13.	Percer	t of C	lass Represented by Amount in Row (11)		
	9.5%				
14.		of Rep	orting Person (See Instructions)		
	CO				

1.	Names of Reporting Persons.				
	Nan Fung Group Holdings Limited				
2.					
	(a) □	(I			
3.	SEC U	Jse On	nlv		
	020 0	01.	" "		
4.	Source	of Fu	ands (See Instructions)		
	AF				
5.		if Dis	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citizei	nship (or Place of Organization		
	British	ı Virgi	n Islands		
		7.	Sole Voting Power		
Nui	mber of		0		
S	hares	8.	Shared Voting Power		
	eficially ned by				
	Each		4,494,851		
	porting	9.	Sole Dispositive Power		
	erson With		0		
	,,,,,,,	10.	Shared Dispositive Power		
			4,494,851		
11.	Aggre	gate A	mount Beneficially Owned by Each Reporting Person		
			and the state of t		
	4,494,				
12.	Check	if the	Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)		
13.	Percer	t of C	lass Represented by Amount in Row (11)		
	9.5%				
14.		of Ren	orting Person (See Instructions)		
	7.5	P			
	CO				

Item 3. Source and Amount of Funds or Other Consideration

Item 3 is amended and supplemented as follows:

On August 1, 2023, Pivotal and Pivotal II purchased an aggregate of 833,333 shares of Common Stock in connection with a secondary offering conducted by the Issuer for an aggregate purchase price of \$3,999,998.

Item 5. Interest in Securities of the Issuer

Item 5 is amended and supplemented as follows:

- (a) The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 47,319,480 outstanding shares of Common Stock, as reported by the Issuer in its Prospectus Supplement filed with the Securities and Exchange Commission on July 28, 2023.
- (c) On August 1, 2023, Pivotal and Pivotal II purchased an aggregate of 833,333 shares of Common Stock in connection with a secondary offering conducted by the Issuer. The shares of Common Stock were purchased for \$4.80 per share and an aggregate purchase price of \$3,999,998.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: August 7, 2023

PIVOTAL BIOVENTURE PARTNERS FUND I, L.P.

By: PIVOTAL BIOVENTURE PARTNERS FUND I G.P., L.P.

Its General Partner,

By: PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD

Its General Partner,

By: /s/ Robert Hopfner

Robert Hopfner Authorized Signatory

PIVOTAL BIOVENTURE PARTNERS FUND II, L.P.

By: PIVOTAL BIOVENTURE PARTNERS FUND II G.P. LTD

Its General Partner,

By: /s/ Peter Tuxen Bisgaard

Peter Tuxen Bisgaard

Director

PIVOTAL BIOVENTURE PARTNERS FUND II G.P. LTD

By: /s/ Peter Tuxen Bisgaard

Peter Tuxen Bisgaard

Director

PIVOTAL BIOVENTURE PARTNERS FUND I G.P., I. P

By: PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD

Its General Partner,

By: /s/ Robert Hopfner

Robert Hopfner Authorized Signatory

PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD

By: /s/ Robert Hopfner

Robert Hopfner Authorized Signatory

PIVOTAL PARTNERS LTD

By: /s/ Sun Xintong

Name: Sun Xintong
Title: Director

PIVOTAL LIFE SCIENCES HOLDINGS LIMITED

By: /s/ Sun Xintong

Name: Sun Xintong Title: Director

NAN FUNG LIFE SCIENCES HOLDINGS LIMITED

By: /s/ Sun Xintong

Sun Xintong Director

NF INVESTMENT HOLDINGS LIMITED

By: /s/ Tang Chun Wai Nelson

Tang Chun Wai Nelson

Director

NAN FUNG GROUP HOLDINGS LIMITED

By: /s/ Tang Chun Wai Nelson

Tang Chun Wai Nelson

Director